News stories about Align Technology (NASDAQ:ALGN) have trended somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Align Technology earned a news impact score of 0.10 on Accern’s scale. Accern also assigned headlines about the medical equipment provider an impact score of 46.0139402243092 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the headlines that may have effected Accern Sentiment’s rankings:

Shares of Align Technology (NASDAQ:ALGN) opened at 176.74 on Friday. Align Technology has a 1-year low of $83.27 and a 1-year high of $179.76. The firm has a market cap of $14.17 billion, a price-to-earnings ratio of 60.53 and a beta of 1.55. The stock has a 50 day moving average of $168.03 and a 200-day moving average of $137.68.

Align Technology (NASDAQ:ALGN) last issued its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.12. The business had revenue of $356.50 million during the quarter, compared to the consensus estimate of $343.43 million. Align Technology had a net margin of 19.18% and a return on equity of 23.87%. The company’s revenue was up 32.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.62 EPS. Equities analysts anticipate that Align Technology will post $3.40 EPS for the current fiscal year.

A number of brokerages have issued reports on ALGN. Bank of America Corporation upgraded shares of Align Technology from a “neutral” rating to a “buy” rating and upped their price target for the company from $175.00 to $193.00 in a research note on Friday, July 28th. Stifel Nicolaus restated a “buy” rating and set a $205.00 price target (up previously from $200.00) on shares of Align Technology in a research note on Monday, August 7th. Credit Suisse Group restated an “outperform” rating and set a $170.00 price target (up previously from $140.00) on shares of Align Technology in a research note on Thursday, July 13th. Zacks Investment Research lowered shares of Align Technology from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 21st. Finally, Jefferies Group LLC restated a “buy” rating and set a $150.00 price target on shares of Align Technology in a research note on Thursday, June 1st. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Align Technology currently has an average rating of “Buy” and a consensus price target of $174.40.

TRADEMARK VIOLATION WARNING: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at

About Align Technology

Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.

Insider Buying and Selling by Quarter for Align Technology (NASDAQ:ALGN)

Receive News & Stock Ratings for Align Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology Inc. and related stocks with our FREE daily email newsletter.